HER2 amplification and overexpression is not present in pediatric osteosarcoma: A tissue microarray study

Pediatric and Developmental Pathology

Volumn 8, Issue 5, 2005, Pages 525-532

  Somers, Gino R ^a,b   Ho, Michael ^a   Zielenska, Maria ^a,b   Squire, Jeremy A ^b,c   Thorner, Paul S ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

CISH; HER2; Immunohistochemistry; Osteosarcoma; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADOLESCENT; ARTICLE; CANCER SURGERY; CARTILAGE CELL; CELL MEMBRANE; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROBLAST; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; METASTASIS; OSTEOBLAST; OSTEOSARCOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TISSUE MICROARRAY; TUMOR BIOPSY;

ADOLESCENT; BONE NEOPLASMS; CHILD; CHROMOGENIC COMPOUNDS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 27844591419     PISSN: 10935266     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10024-005-0044-5     Document Type: Article

References (35)

1. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
2. Ellis IO, Schnitt SJ, Sastre-Garau X, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours: Tumours of the Breast and Female Genital Organs. IARC Press: Lyon. 2003; p 13-112.
3. Marte BM, Graus-Porta D, Jeschke M, et al. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells. Oncogene 1995;10:167-175.
4. Tsuda HH. Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancer. Breast Cancer 2001;8:38-44.
5. Tsongalis GJ, Ried A Jr. HER2: the neu prognostic marker for breast cancer. Crit Rev Clin Lab Sci 2001;38:167-182.
6. Nuciforo PG, Pellegrini C, Fasani R, et al. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum Pathol 2003;34:639-645.
7. Mark HF, Brown S, Sun CL, et al. Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology 1998;66:59-63.
8. Foster H, Knox S, Ganti AK, et al. HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas. Am J Clin Oncol 2003;26:188-191.
9. Nasu K, Kawano Y, Hirota Y, et al. Immunohistochemical study of c-erb B-2 expression in malignant mixed mullerian tumors of the female genital tract. J Obstet Gynaecol Res 1996;22:347-351.
10. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-1404.
11. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004;40:963-970.
12. Zhou H, Randall RL, Brothman AR, et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32.
13. Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours: Tumours of Soft Tissue and Bone. IARC Press: Lyon. 2002; p 264-270.
14. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-1230.
15. Simon R, Mirlacher M, Sauter G. Tissue microarrays. Biotechniques 2004;36:98-105.
16. Zhao J, Wu R, Au A, et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002;15:657-665.
17. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
18. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
19. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997;44:973-989.
20. Dickens DS, Kozielski R, Leavey PJ, et al. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 2003;25:282-285.
21. Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 2002;26:486-492.
22. Boehm AK, Neff JR, Squire JA, et al. Cytogenetic findings in 36 osteosarcoma specimens and a review of the literature. Pediatr Pathol Mol Med 2000;19:359-376.
23. Al-Romaih K, Bayani J, Vorobyova J, et al. Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genet Cytogenet 2003;144:91-99.
24. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77:71-78.
25. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004;100:1936-1942.
26. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-2788.
27. Tsai JY, Aviv H, Benevenia J, et al. HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest 2004;22:16-24.
28. Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 2001;14:1277-1283.
29. Maitra A, Wanzer D, Weinberg AG, et al. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 2001;92:677-683.
30. Thomas DG, Giordano TJ, Sanders D, et al. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002;8:788-793.
31. Brown RS, Edwards J, Bartlett JW, et al. Routine acid decalcification of bone marrow samples can preserve DNA for FISH and CGH studies in metastatic prostate cancer. J Histochem Cytochem 2002;50:113-115.
32. Hoang MP, Sahin AA, Ordonez NG, et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113:852-859.
33. Wickham CL, Sarsfield P, Joyner MV, et al. Formic acid decalcification of bone marrow trephines degrades DNA: alternative use of EDTA allows the amplification and sequencing of relatively long PCR products. Mol Pathol 2000;53:336.
34. Vera-Roman JM, Rubio-Martinez LA. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med 2004;128:627-633.
35. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-1472.